Pharming Group N.V. (PHAR)
About Pharming Group N.V.
Pharming Group is a biotechnology company focused on developing and commercializing therapies for rare and ultra-rare diseases, particularly immunological and genetic conditions with high unmet need. It operates as an integrated company with capabilities across clinical development, manufacturing, regulatory affairs, and commercialization, supported by scientific and operational expertise. It leverages its efficient infrastructure to expand its pipeline and improve patient access to treatment. The Company operates in the United States, Europe, and the rest of the world, with the United States contributing the majority of its revenue.
This profile is unclaimed. An authorized representative can claim it to add details and earn the Verified badge.
Financial summary
- Market cap
- $885.7M
15-minute delayed · data by Polygon.io
Past year · hover for prices
52-week range
- Market cap
- $885.7M
- Shares outstanding
- 70.2M
- Open
- —
- Day range
- –
- Prev close
- —
- Volume
- —
- IPO date
- Dec 23, 2020
Pharming Group N.V. (PHAR) Stock Price
- Trading 40% below its 52-week high.
Automatically generated from public filings and market data. Informational only — not investment advice or a recommendation to buy or sell any security.
No reviews yet. Be the first to review Pharming Group N.V..
Write a review
News about Pharming Group N.V.
News & sentiment via Polygon.io
Pharming Group N.V.: frequently asked questions
Is Pharming Group N.V. an American company?
Pharming Group N.V. is a US-based company, listed in the americancompanies.com directory of American companies. Its American-origin credentials have not yet been independently verified.
Is Pharming Group N.V. publicly traded?
Yes — Pharming Group N.V. is a publicly traded company. Its stock trades under the ticker symbol PHAR on the NASDAQ.
What does Pharming Group N.V. do?
Pharming Group N.V. is an American Pharmaceuticals company in the Health & Beauty sector.
